• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.

作者信息

Papatheodoridis George V, Voulgaris Thodoris, Papatheodoridi Margarita, Kim W Ray

机构信息

Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greeces.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA.

出版信息

Hepatology. 2020 Dec;72(6):2197-2205. doi: 10.1002/hep.31440. Epub 2020 Nov 13.

DOI:10.1002/hep.31440
PMID:32602980
Abstract
摘要

相似文献

1
Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.慢性乙型肝炎中肝细胞癌的风险评分：精准医学的前景
Hepatology. 2020 Dec;72(6):2197-2205. doi: 10.1002/hep.31440. Epub 2020 Nov 13.
2
Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?亡羊补牢：我们是否应该治疗免疫耐受期慢性乙型肝炎患者以预防肝细胞癌？
Gastroenterology. 2020 Jun;158(8):2028-2032. doi: 10.1053/j.gastro.2020.02.027. Epub 2020 Feb 20.
3
Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.抗病毒治疗对慢性病毒性肝炎患者肝细胞癌风险的影响。
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1277-1282. doi: 10.1097/MEG.0000000000001254.
4
Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B.慢性乙型肝炎患者停止长期核苷（酸）类似物治疗面临的挑战
Gastroenterology. 2020 Apr;158(5):1185-1190. doi: 10.1053/j.gastro.2019.10.050. Epub 2019 Dec 4.
5
[Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma].[干扰素联合利巴韦林治疗与肝细胞癌的发生]
Orv Hetil. 2010 Jul 18;151(29):1177-81. doi: 10.1556/OH.2010.28925.
6
Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.有效抑制病毒对于降低慢性乙型肝炎肝硬化患者肝细胞癌的发生是必要的：一项10年随访结果
Medicine (Baltimore). 2017 Nov;96(44):e8454. doi: 10.1097/MD.0000000000008454.
7
Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.抗病毒治疗乙型肝炎相关失代偿性肝硬化患者的长期结局。
World J Gastroenterol. 2018 Oct 28;24(40):4606-4614. doi: 10.3748/wjg.v24.i40.4606.
8
Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.基于改良 FIB-4 指数对恩替卡韦治疗的慢性乙型肝炎患者进行肝细胞癌风险分层。
J Gastroenterol Hepatol. 2019 Feb;34(2):442-449. doi: 10.1111/jgh.14372. Epub 2018 Jul 19.
9
Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.血清 Mac-2 结合蛋白糖基化异构体与恩替卡韦治疗的慢性乙型肝炎患者肝细胞癌的风险。
J Gastroenterol Hepatol. 2019 Oct;34(10):1817-1823. doi: 10.1111/jgh.14637. Epub 2019 Mar 10.
10
Preventing infection-associated cancer: from bench to hillside.预防感染相关癌症：从实验室到临床实践
J Natl Cancer Inst. 2005 Feb 16;97(4):245-6. doi: 10.1093/jnci/dji059.

引用本文的文献

1
Prediction of the early hepatocellular carcinoma development in patients with chronic hepatitis B virus infection using gadoxetic acid-enhanced magnetic resonance imaging.应用钆塞酸增强磁共振成像预测慢性乙型肝炎病毒感染患者的早期肝细胞癌发生。
BMC Cancer. 2024 Nov 19;24(1):1425. doi: 10.1186/s12885-024-13185-7.
2
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis.早期治疗期间HBeAg血清学清除与肝细胞癌或失代偿期肝硬化发生之间无关联。
JHEP Rep. 2024 Apr 8;6(7):101089. doi: 10.1016/j.jhepr.2024.101089. eCollection 2024 Jul.
3
Albumin-bilirubin grade as a predictor of survival in hepatocellular carcinoma patients with thrombocytopenia.
白蛋白-胆红素分级作为血小板减少的肝细胞癌患者生存的预测指标
World J Gastrointest Oncol. 2024 May 15;16(5):1763-1772. doi: 10.4251/wjgo.v16.i5.1763.
4
Long noncoding RNA RP11-241J12.3 targeting pyruvate carboxylase promotes hepatocellular carcinoma aggressiveness by disrupting pyruvate metabolism and the DNA mismatch repair system.靶向丙酮酸羧化酶的长链非编码RNA RP11-241J12.3通过破坏丙酮酸代谢和DNA错配修复系统促进肝细胞癌的侵袭性。
Mol Biomed. 2022 Feb 5;3(1):4. doi: 10.1186/s43556-021-00065-w.
5
Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma.病毒性肝炎相关肝细胞癌的危险因素与预防
Front Oncol. 2021 Sep 9;11:686962. doi: 10.3389/fonc.2021.686962. eCollection 2021.
6
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B.治疗期间肝脏硬度对慢性乙型肝炎患者肝细胞癌发生的预后作用
J Hepatocell Carcinoma. 2021 May 25;8:467-476. doi: 10.2147/JHC.S300382. eCollection 2021.
7
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B.新型亚洲肝细胞癌风险评分对接受治疗的慢性乙型肝炎白种人的预测性能。
JHEP Rep. 2021 Apr 20;3(3):100290. doi: 10.1016/j.jhepr.2021.100290. eCollection 2021 Jun.
8
Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control.丙型肝炎病毒根除或乙型肝炎病毒控制后肝细胞癌风险的分层
J Clin Med. 2021 Jan 19;10(2):353. doi: 10.3390/jcm10020353.